← back to search

Carsten Nieder

Nordland Hospital · NO
Area of research
Pulmonary and Respiratory Medicine · Genetics
Research interest
Research interests include Brain Metastases and Treatment, Glioma Diagnosis and Treatment, Management of metastatic bone disease, and Lung Cancer Research Studies.
h-index
49
citations
10,297
works
942
NIH funding
primary concept
Medicine
email

Recent publications

Radiotherapy at the limits of age: evolving fractionation strategies, symptom palliation, and survival in nonagenarians
Radiotherapy and Oncology 2026cited by 0position: contributordoi
Ongoing prospective studies on reirradiation: A systematic review of a clinical trials database.
2025cited by 11position: contributordoi
External Validation of an Extended Prognostic Assessment Model in Patients With Brain Metastases from Small‐cell Lung Cancer
Cancer Diagnosis & Prognosis 2025cited by 1position: firstdoi
Consequences of adverse events in cancer immunotherapy combinations - a comprehensive real-world analysis.
2025cited by 0position: contributordoi
Patient-reported symptoms before adjuvant locoregional radiotherapy for breast cancer: triple-negative histology impacts the symptom burden.
2024cited by 0position: contributordoi
PRO: Do We Still Need Whole-Brain Irradiation for Brain Metastases?
Cancers 2023cited by 15position: middledoi
Prospective randomized clinical studies involving reirradiation: update of a systematic review.
2023cited by 10position: contributordoi
Palliative appropriateness criteria: external validation of a new method to evaluate the suitability of palliative radiotherapy fractionation.
2023cited by 3position: contributordoi
The LabPS score: Inexpensive, Fast, and Site-agnostic Survival Prediction.
2023cited by 1position: contributordoi
European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making
The Lancet Oncology 2022cited by 187position: lastdoi
30-day mortality in patients treated for brain metastases: extracranial causes dominate.
2022cited by 9position: contributordoi
Primary systemic therapy for patients with brain metastases from lung cancer ineligible for targeted agents.
2022cited by 3position: contributordoi
Feasibility and efficacy of early docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in a rural health care setting.
2022cited by 1position: contributordoi
Palliative non-small cell lung cancer treatment and end-of-life care stratified by sex and childlessness: an important interplay in unmarried patients?
2022cited by 0position: contributordoi
Hippocampus-Avoidance Whole-Brain Radiation Therapy Is Efficient in the Long-Term Preservation of Hippocampal Volume
Frontiers in Oncology 2021cited by 27position: middledoi
New clinical data on human spinal cord re-irradiation tolerance.
2021cited by 16position: contributordoi
Assessment of extracranial metastatic disease in patients with brain metastases: How much effort is needed in the context of evolving survival prediction models?
2021cited by 7position: contributordoi
Hippocampus‐avoidance whole‐brain radiation therapy with a simultaneous integrated boost for multiple brain metastases
Cancer 2020cited by 74position: middledoi
Radiotherapy for nonagenarians: the value of biological versus chronological age
Radiation Oncology 2020cited by 19position: middledoi
Long-term survival results after treatment for oligometastatic brain disease
Reports of Practical Oncology & Radiotherapy 2020cited by 15position: firstdoi
Long-term survival results after treatment for oligometastatic brain disease.
2020cited by 12position: contributordoi
Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer.
2020cited by 7position: contributordoi
Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA)
Radiation Oncology 2020cited by 6position: firstdoi
Validation of the graded prognostic assessment for gastrointestinal cancers with brain metastases (GI-GPA).
2020cited by 5position: contributordoi
Provider decision regret-a useful method for analysis of palliative thoracic re-irradiation for lung cancer?
2020cited by 4position: contributordoi
Feasibility and efficacy of sequential systemic therapy for metastatic castration-resistant prostate cancer in a rural health care setting.
2020cited by 4position: contributordoi
Risk factors for esophagitis after hypofractionated palliative (chemo)radiotherapy for non-small cell lung cancer
2020cited by 0position: contributordoi
Is there a seasonal variation of survival after systemic chemotherapy for metastatic castration-resistant prostate cancer in a rural part of North Norway?
2020cited by 0position: contributordoi
Risk factors for esophagitis after hypofractionated palliative (chemo)radiotherapy for non-small cell lung cancer
2020cited by 0position: contributordoi
Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous.
2019cited by 21position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 24 papers (2019–2026)Anca‐Ligia Grosu · German Marine Research Consortium21 papers (2015–2025)Angelika Bilger · Deutschen Konsortium für Translationale Krebsforschung10 papers (2016–2020)Ilinca Popp · University of Freiburg8 papers (2018–2025)Oliver Oehlke · Kliniken Maria Hilf8 papers (2015–2018)Mandy Hintz · Creighton University8 papers (2017–2020)Ellinor Haukland · University of Stavanger5 papers (2019–2025)Horst Urbach · Brain (Germany)5 papers (2016–2021)Matthias Gückenberger · Stadtspital Waid5 papers (2017–2025) · 4 papers (2015–2021)Jamina Tara Fennell · University Medical Center Freiburg4 papers (2017–2021)Maximilian Niyazi · Cancer Research Center3 papers (2017–2022)Johannes A. Langendijk · Hanze University of Applied Sciences3 papers (2017–2022)Thomas Rothe · University Medical Center Freiburg3 papers (2019–2021)Michael D. Chan · Oklahoma City University2 papers (2017–2018)Panagiotis Balermpas · University of Zurich2 papers (2022–2025)Dieter Henrik Heiland · German Cancer Society2 papers (2019–2020)Christina Tsien · McGill University Health Centre2 papers (2017–2018) · 2 papers (2017–2018)Steve Braunstein · Pediatric Brain Tumor Foundation2 papers (2017–2018)